MAP2K2
ENSG00000126934
Target class
Kinase
Chromosome
19
Approved drugs
7
Clinical candidates (approved and in development)
19
- Approved drugs
- 7
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 19
- Chemical probe available
- Yes
- Target name
- MAP2K2
- Gene name
- Mitogen-activated protein kinase kinase 2
- Gene symbol
- MAP2K2
- Previous gene symbols
- PRKMK2
- Protein name
- Dual specificity mitogen-activated protein kinase kinase 2 (MAP kinase kinase 2) (MAPKK 2) (EC 2.7.12.2) (ERK activator kinase 2) (MAPK/ERK kinase 2) (MEK 2)
- MEK2
- MKK2
- Gene biotype
- Protein coding
- Gene family
- Mitogen-activated protein kinase kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 196.94
- Tissue specificity (Gini)
- 0.161
- Tissue specificity (tau)
- 0.567
- KEGG gene identifiers
- hsa:5605
- Protein interaction confidence
- 0.905103
- Protein interaction partners
- 39
- R-HSA-112411
- R-HSA-170968
- R-HSA-445144
- R-HSA-5210891
- R-HSA-5673000
- R-HSA-5674135
- R-HSA-5674499
- R-HSA-6802946
- R-HSA-6802948
- R-HSA-6802952
- R-HSA-6802955
- R-HSA-9649948
- R-HSA-9652169
- R-HSA-9656223
- End position
- 4124216
- Start position
- 4090317
- Chromosome
- 19
- Strand
- Reverse
- Cytoplasm . Membrane
- Peripheral membrane protein . Note=Membrane localization is probably regulated by its interaction with KSR1. .
- Cytosol
- End piece
- Mid piece
- Principal piece
Publication evidence
- PubMed 10409742
- Tissue specificity (tau)
- 0.567058
- Expression inequality (Gini)
- 0.160987
Expression in transcripts per million
- Testis
- 196.94
- Cells - Cultured fibroblasts
- 128.84
- Cells - EBV-transformed lymphocytes
- 125.26
- Brain - Cerebellum
- 117.99
- Cervix - Ectocervix
- 115.76
Expression in transcripts per million
- Testis196.94
- Cells - Cultured fibroblasts128.84
- Cells - EBV-transformed lymphocytes125.26
- Brain - Cerebellum117.99
- Cervix - Ectocervix115.76
- Pituitary115.06
- Prostate114.32
- Brain - Cerebellar Hemisphere113.56
- Ovary112.99
- Cervix - Endocervix109.78
- Muscle - Skeletal108.12
- Uterus107.47
- Nerve - Tibial104.51
- Thyroid100.58
- Esophagus - Mucosa99.53
- Brain - Cortex98.71
- Skin - Sun Exposed (Lower leg)97.75
- Spleen97.52
- Brain - Frontal Cortex (BA9)96.5
- Whole Blood96.4
- Small Intestine - Terminal Ileum95.03
- Fallopian Tube94.98
- Vagina93.15
- Skin - Not Sun Exposed (Suprapubic)91.95
- Colon - Sigmoid91.26
And 29 more, listed on the interactive page.
- GO:0010628
- GO:0032872
- GO:0036289
- GO:0045893
- GO:0070371
- GO:0071902
- GO:0090170
- GO:2000641
- GO:0005634
- GO:0005737
- GO:0005739
- GO:0005769
- GO:0005770
- GO:0005778
- GO:0005783
- GO:0005794
- GO:0005829
- GO:0005874
- GO:0005911
- GO:0005925
- GO:0009898
- GO:0016020
- GO:0048471
- GO:0004674
- GO:0004708
- GO:0004712
- GO:0004713
- GO:0005078
- GO:0005515
- GO:0030165
- GO:0043539
- GO:0097110
- GO:0106310
Related records
Trials (1,098)
- "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma
- "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
- (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma
- 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
- 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
- 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
- A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
- A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)
- A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
- A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
- A Clinical Trial of Patients With Melanoma
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
- A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
- A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism
- A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data
- A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
- A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects
Drugs (19)
- AS-703988 Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Avutometinib Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- AZD-8330 Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Balamapimod Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Binimetinib Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- CI-1040 Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Cobimetinib Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Cobimetinib fumarate Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Mirdametinib Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Pimasertib Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Refametinib Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- RG-7167 Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
- RO-4987655 Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Selumetinib Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Selumetinib sulfate Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
- TAK-733 Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- Trametinib Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
- Trametinib dimethyl sulfoxide Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- WX-554 Dual specificity mitogen-activated protein kinase kinase 2 inhibitor